1‐deamino‐8‐D‐arginine vasopressin (DCAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass
- 1 July 1994
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 46 (3) , 199-207
- https://doi.org/10.1002/ajh.2830460308
Abstract
1‐deamino‐8‐D‐Arginine vasopressin (DDAVP) shortens the bleeding time in some patients with platelet dysfunction and decreases blood loss in some cardiopulmonary bypass patients. We studied platelet membrane glycoproteins in patients with von Willebrand disease (vWD), disorders of platelet function, and in cardiopulmonary bypass patients after infusion of 0.3 μg/kg of DDAVP. Platelets from 8 cardiopulmonary bypass patients, receiving DDAVP immediately after surgery, were compared to those of 14 patients not receiving DDAVP. We also studied 12 patients with vWD, and 8 patients with platelet dysfunction receiving DDAVP. Fixed platelets, stained with monoclonal fluorescein (FITC)‐labeled antibodies directed against GPIb (CD42b antigen), GPIb/IX, GPIIb/IIIa (CD41a antigen), CD63 antigen (a platelet activation protein), and P‐selectin (CD62 antigen) were studied by flow cytometry. Binding of CD42b monoclonal antibody (MoAb) and anti‐GPIb/IX to platelets from both groups of bypass patients increased during the 18–20 hr after surgery, but the group receiving DDAVP showed the greater increase (P = 0.032). Platelets from patients receiving DDAVP for vWD or for platelet dysfunction, had increases in CD42b MoAb and anti‐GPIb/IX binding (P < 0.01) that coincided with shortening of their bleeding time. No changes were seen in binding of other antibodies. When platelets from normal donors were incubated with DDAVP for 20 hr, there were increases in platelet surface CD42b MoAb binding, while immunogold‐stained transmission electron micrographs of permeabilized platelets demonstrated decreases in cytoplasmic CD42b MoAb binding. DDAVP increases platelet membrane GPIb expression in a variety of patients and may account for improvement in hemostasis seen in some studies. Redistribution of GPIb from the cytoplasm to the membrane may account for this increased expression.Keywords
This publication has 47 references indexed in Scilit:
- DDAVP‐induced enhancement of platelet retention: Its dependence on platelet‐von Willebrand Factor and the platelet receptor GP IIb/IIIaEuropean Journal of Haematology, 1992
- Reduction of platelet glycoprotein Ib in uraemiaBritish Journal of Haematology, 1991
- A Trial of Desmopressin (1-Desamino-8-D-Arginine Vasopressin) to Reduce Blood Loss in Uncomplicated Cardiac SurgeryNew England Journal of Medicine, 1989
- Response to desmopressin in type IID von Willebrand's diseaseClinical and Laboratory Haematology, 1989
- Platelet glass bead retention is useful in monitoring response to 1‐deamino‐8‐D‐arginine‐vasopressin (d‐DAVP)American Journal of Hematology, 1989
- Hermansky‐pudlak syndrome: Correction of bleeding time by 1‐desamino‐8D‐arginine vasopressinAmerican Journal of Hematology, 1989
- Treatment with Desmopressin Acetate to Reduce Blood Loss after Cardiac SurgeryNew England Journal of Medicine, 1986
- Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in UremiaNew England Journal of Medicine, 1983
- Platelets in Myeloproliferative Disorders. III: Glycoprotein Profile in Relation to Platelet Function and Platelet DensityScandinavian Journal of Haematology, 1981
- Glycoprotéines de surface altérées des plaquettes de leucémie myéloïde chronique. Altered platelet surface glycoproteins in chronic myeloid leukemiaInternational Journal of Cancer, 1977